Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: A randomized, phase III trial

Veterinary and Comparative Oncology

Volumn 14, Issue 1, 2016, Pages 81-87

  Skorupski, K A ^a   Uhl, J M ^a,b   Szivek, A ^a,c   Allstadt Frazier, S D ^a,d   Rebhun, R B ^a   Rodriguez, C O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Veterinary Specialty Center of Tucson   (United States)

^d UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Amputation; Bone tumour; Canine; Chemotherapy; Clinical trial

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOXORUBICIN;

ADJUVANT CHEMOTHERAPY; ANIMAL; BONE NEOPLASMS; CONTROLLED STUDY; DOG; DOG DISEASES; OSTEOSARCOMA; RANDOMIZED CONTROLLED TRIAL; VETERINARY;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DOG DISEASES; DOGS; DOXORUBICIN; OSTEOSARCOMA;

EID: 84956596640     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/vco.12069     Document Type: Article

References (18)

1. Straw RC, Withrow SJ, Richter SL, Powers BE, Klein MK, Postorino NC, LaRue SM, Ogilvie GK, Vail DM, Morrison WB, McGee M and Dickinson K. Amputation and cisplatin for the treatment of canine osteosarcoma. Journal of Veterinary Internal Medicine 1991; 5: 205-210.
2. Berg J, Weinstein MJ, Schelling SH and Rand WM. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-1990). Journal of the American Veterinary Medical Association 1992; 200: 2005-2008.
3. Bergman PJ, MacEwen EG, Kurzman ID, Henry CJ, Hammer AS, Knapp DW, Hale A, Kruth SA, Klein MK, Klausner J, Norris AM, McCaw D, Straw RC and Withrow SJ. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). Journal of Veterinary Internal Medicine 1996; 10: 76-81.
4. Phillips B, Powers BE, Dernell WS, Straw RC, Khanna C, Hogge GS and Vail DM. Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs. Journal of the American Animal Hospital Association 2009; 45: 33-38.
5. Saam DE, Liptak JM, Stalker MJ and Chun R. Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996-2006). Journal of the American Veterinary Medical Association 2011; 238: 195-206.
6. Berg J, Weinstein MJ, Springfield DS and Rand WM. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. Journal of the American Veterinary Medical Association 1995; 206: 1555-1560.
7. Kent MS, Strom A, London CA and Seguin B. Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs. Journal of Veterinary Internal Medicine 2004; 18: 540-544.
8. Bacon NJ, Ehrhart NP, Dernell WS, Lafferty M and Withrow SJ. Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999-2006). Journal of the American Veterinary Medical Association 2008; 232: 1504-1510.
9. Ehrhart NP, Ryan SD and Fan TM. Tumors of the skeletal system. In: Withrow & MacEwen's Small Animal Clinical Oncology. 5 edn., SJ Withrow, DM Vail and RL Page Eds., St. Louis, Elsevier, 2013: 463-503.
10. Veterinary Co-operative Oncology Group. Veterinary co-operative oncology Group-Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2004; 2: 195-213.
11. Lascelles BDX, Dernell WS, Correa MT, Lafferty M, Devitt CM, Kuntz CA, Straw RC and Withrow SJ. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. Annals of Surgical Oncology 2005; 12: 1073-1083.
12. Boerman I, Selvarajah GT, Nielen M and Kirpensteijn J. Prognostic factors in canine appendicular osteosarcoma-a meta-analysis. BMC Veterinary Research 2012; 8: 56.
13. Ehrhart N, Dernell WS, Hoffman WE, Weigel RM, Powers BE and Withrow SJ. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990-1996). Journal of the American Veterinary Medical Association 1998; 213: 1002-1006.
14. Garzotto CK, Berg J, Hoffman WE and Rand WM. Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. Journal of Veterinary Internal Medicine 2000; 14: 587-592.
15. Kirpensteijn J, Kik M, Rutteman GR and Teske E. Prognostic significance of a new histologic grading system for canine osteosarcoma. Veterinary Pathology 2002; 39: 240-246.
16. Loukopoulos P and Robinson WF. Clinicopathologic relevance of tumor grading in canine osteosarcoma. Journal of Comparative Pathology 2007; 136: 65-73.
17. Misdorp W and Hart AA. Some prognostic and epidemiologic factors in canine osteosarcoma. J Nat Cancer Inst. 1979; 62: 537-545.
18. Hammer AS, Weeren FR, Weisbrode SE and Padgett SL. Prognostic factors in dogs with osteosarcoma of the flat or irregular bones. Journal of the American Animal Hospital Association 1995; 31: 321-326.